InMed Pharmaceuticals
- Company typePublic
- Founded1981
- HeadquartersVancouver, Canada
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
InMed Pharmaceuticals firmographics
Firmographics- Name
- InMed Pharmaceuticals
- Legal name
- InMed Pharmaceuticals Inc.
- Website
- https://inmedpharma.com
- Company type
- Public
- Founded year
- 1981
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
InMed Pharmaceuticals industry classification
Industry- Product category
- Biopharmaceutical Drug Development
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)
- akta.pro secondary industries
- Rare Neurology & Neurodegenerative Disorder Therapies (HLAIAIAD), Headache & Migraine Medicine (HLAKAIAE)
Keywords
Where InMed Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Vancouver
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
InMed Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Pharmaceutical Development: Revenue generation through development of drug candidates targeting Alzheimer's disease (INM-901), dry AMD (INM-089), and migraine prevention (via Mentari Therapeutics merger MT-001, MT-002). Currently pre-revenue as all programs are in preclinical/clinical stage.
- BayMedica Commercial Cannabinoid Sales: Commercial sales of rare, non-intoxicating cannabinoids through BayMedica subsidiary to the health and wellness sector. Revenue declining 26% YoY to $0.8M in Q2 FY2026. Operations being wound down by June 30, 2026 due to U.S. legislation H.R. 5371.
- Capital Markets / Private Placements: Revenue through capital raises including private placements, registered direct offerings, and at-the-market share offerings to fund pipeline development and operations. Major transactions include $6M (Sept 2022), $5M (June 2022), $12M (July 2021), and $290M private placement for Mentari merger (May 2026).
Go-to-market motion2 records
Distribution channels1 record
Marketing channels1 record
InMed Pharmaceuticals product offering
Product offeringCore offering
InMed Pharmaceuticals is a clinical-stage biopharmaceutical company developing proprietary cannabinoid-based and biologic drug candidates targeting high unmet medical needs. Core pipeline assets include INM-901 for Alzheimer's disease (targeting neuroinflammation via endocannabinoid CB1/CB2 receptors) and INM-089 for dry age-related macular degeneration, with the SVN-SDN-14 series (antidepressant activity) as additional pipeline candidates. Post-merger with Mentari Therapeutics (May 2026), the company will add migraine prevention candidates MT-001 (anti-PACAP antibody) and MT-002 (anti-CGRP x PACAP bispecific). The BayMedica subsidiary historically supplied rare non-intoxicating cannabinoids to the health and wellness sector but is being wound down by June 30, 2026.
Product overview
InMed Pharmaceuticals is a pharmaceutical company focused on drug development for high unmet medical needs. The company's core pipeline includes INM-901 for Alzheimer's disease and INM-089 for dry age-related macular degeneration. Through its subsidiary BayMedica (acquired September 2021), it previously manufactured rare cannabinoids for health and wellness, though this commercial segment is being wound down by June 2026. The company has announced a merger with Mentari Therapeutics to add migraine prevention candidates MT-001 and MT-002 to its portfolio. InMed historically developed small molecule drug candidates targeting CB1/CB2 receptors.
Differentiator
Problem solved
Functional benefit
Products and services
- INM-901 INM-901 is a proprietary drug candidate for Alzheimer's disease targeting neuroinflammation via the endocannabinoid system (CB1/CB2 receptors). Preclinical data in 3D human brain organoid models and animal studies demonstrate dose-dependent reduction of pro-inflammatory markers IL-6 and IL-8, with neuroprotection, neuritogenesis, and behavioral improvements. Pharmacokinetic studies showed robust bioavailability with no adverse neurological effects in large animal models.
- INM-089 INM-089 is a drug candidate for the treatment of dry age-related macular degeneration (dry AMD), addressing an unmet medical need where no approved disease-modifying therapies currently exist. The candidate is advancing toward a pre-IND meeting with the FDA in Q4 2026.
- SVN-SDN-14 Series Compounds The SVN-SDN-14 series consists of patent-pending small molecule drug candidates targeting the endocannabinoid system with demonstrated antidepressant-like activity benchmarked against fluoxetine (Prozac), supporting potential therapeutic applications for patients with inadequate SSRI response.
- MT-001 (post-Mentari merger) MT-001 is an anti-PACAP antibody targeting migraine prevention through a mechanism distinct from the CGRP pathway, addressing unmet need in patients who respond suboptimally to existing approved therapies. Regulatory filing is planned for mid-2026.
- MT-002 (post-Mentari merger) MT-002 is an anti-CGRP x PACAP bispecific antibody for migraine prevention, designed to address patients who respond suboptimally to current approved therapies by targeting both pathways simultaneously. Regulatory filing is planned for Q1 2027.
- BayMedica Rare Cannabinoids BayMedica is a wholly owned subsidiary of InMed Pharmaceuticals that manufactured and sold rare, non-intoxicating cannabinoids for the health and wellness sector using proprietary processes. Commercial operations are being wound down by June 30, 2026 due to anticipated negative impacts from U.S. federal legislation H.R. 5371; revenue was $0.8M in Q2 FY2026, declining 26% YoY.
Quantifiable outcome
- INM-901 demonstrated dose-dependent reduction of IL-6 and IL-8 pro-inflammatory markers in 3D human brain organoid models
- +3 more outcomes
Companies that use InMed Pharmaceuticals
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles3 records
InMed Pharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
InMed Pharmaceuticals partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- Mentari TherapeuticscoreInMed entered into a definitive all-stock merger agreement with Mentari Therapeutics in May 2026. The merger combines Mentari's migraine prevention drug pipeline (MT-001 anti-PACAP antibody, MT-002 anti-CGRP x PACAP bispecific) with InMed's public market infrastructure. The combined entity operates as Mentari Therapeutics on Nasdaq with approximately $421.4 million pro forma equity value.
- Stem Pharm, Inc.coreInMed collaborated with Stem Pharm, Inc. for preclinical validation studies using 3D human brain organoid models to demonstrate INM-901's reduction of neuroinflammation in Alzheimer's disease models. The studies showed dose-dependent reduction of pro-inflammatory markers IL-6 and IL-8, aligning with prior animal model findings.
- BayMedicacoreInMed Pharmaceuticals acquired BayMedica, a US-based company specializing in manufacturing rare cannabinoids, in September 2021. The acquisition aimed to position InMed as a global leader in cannabinoid manufacturing and expand its product pipeline with high-value cannabinoid products. BayMedica's commercial operations are being wound down by June 30, 2026 due to anticipated negative impacts from U.S. legislation H.R. 5371.
Scale indicators6 records
Recent moves7 records
Expansion highlights6 records
InMed Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- Axsome Therapeutics: Clinical-stage-to-commercial CNS specialty pharma with FDA-approved migraine therapy Qulipta (CGRP antagonist) and Auvelity for depression — directly comparable to InMed/Mentari's CNS pipeline focus and indication overlap.
- Tonix Pharmaceuticals: Clinical-stage CNS company developing migraine therapies and other neurological candidates, with comparable small-cap profile and pipeline-stage risk/reward similar to InMed/Mentari.
- Biohaven Pharmaceuticals: Migraine-focused specialty pharma (Nurtec ODT) and CNS pipeline developer — directly comparable therapeutic focus and development stage for the post-merger Mentari migraine assets.
- Sage Therapeutics: CNS specialty pharma with depression and neurology pipeline (Zurzuvae) — comparable clinical-stage CNS drug developer with similar indication overlap to InMed's neurology programs.
- Aelis Farma: Cannabinoid-based pharmaceutical developer focused on CNS disorders, with a CB1-targeting platform — directly comparable mechanism and therapeutic focus to InMed's cannabinoid approach.
Broad incumbents
- Jazz Pharmaceuticals: Specialty pharma with Epidiolex (cannabidiol) and a CNS franchise including migraine therapy — established player with overlapping cannabinoid-pharma and migraine therapeutics comparable to InMed/Mentari's pipeline.
- Lundbeck: Specialty pharma with strong neurology/migraine franchise (Vyepti anti-CGRP) — direct therapeutic-area incumbent comparable to the migraine focus of post-merger pipeline.
- AbbVie: Large pharma with migraine franchise (Ubrelvy CGRP antagonist) and neurology pipeline — comparable therapeutic area and potential strategic acquirer of CNS assets like InMed/Mentari's pipeline.
- Pfizer: Large pharma with migraine asset (Nurtec ODT) via Biohaven acquisition and active CNS investing — comparable migraine therapeutic exposure and potential partnership/acquisition counterparty.
Emerging players
- Corcept Therapeutics: Specialty CNS pharma focused on cortisol-modulating therapies with comparable small/mid-cap profile — comparable scale and commercial-stage CNS drug development model.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
InMed Pharmaceuticals social profiles
Digital presenceInMed Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
InMed Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles6 records
InMed Pharmaceuticals subsidiaries and ownership
Company hierarchySubsidiaries1 record
InMed Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds14 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
InMed Pharmaceuticals M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about InMed Pharmaceuticals
What does InMed Pharmaceuticals do?
InMed Pharmaceuticals is a clinical-stage biopharmaceutical company developing proprietary cannabinoid-based and biologic drug candidates targeting high unmet medical needs. Core pipeline assets include INM-901 for Alzheimer's disease (targeting neuroinflammation via endocannabinoid CB1/CB2 receptors) and INM-089 for dry age-related macular degeneration, with the SVN-SDN-14 series (antidepressant activity) as additional pipeline candidates. Post-merger with Mentari Therapeutics (May 2026), the company will add migraine prevention candidates MT-001 (anti-PACAP antibody) and MT-002 (anti-CGRP x PACAP bispecific). The BayMedica subsidiary historically supplied rare non-intoxicating cannabinoids to the health and wellness sector but is being wound down by June 30, 2026.
Is InMed Pharmaceuticals a public or private company?
InMed Pharmaceuticals is a public company. It is classified as public and is currently operating.
When was InMed Pharmaceuticals founded?
InMed Pharmaceuticals was founded in 1981. It employs 11 to 50 people.
Where is InMed Pharmaceuticals based?
InMed Pharmaceuticals is headquartered in Vancouver, Canada, in the North America region.
How does InMed Pharmaceuticals make money?
Three revenue lines are on record. Pharmaceutical Development is the primary driver. The others are bayMedica Commercial Cannabinoid Sales and capital Markets / Private Placements.
Who are InMed Pharmaceuticals's main competitors?
Direct peers on record are Axsome Therapeutics, Tonix Pharmaceuticals, Biohaven Pharmaceuticals, Sage Therapeutics and Aelis Farma. Broad incumbents are Jazz Pharmaceuticals, Lundbeck, AbbVie and Pfizer. Corcept Therapeutics is listed as an emerging player.
Does InMed Pharmaceuticals have an API?
No public API is recorded for InMed Pharmaceuticals.
What industry is InMed Pharmaceuticals in?
InMed Pharmaceuticals's product category is Biopharmaceutical Drug Development. Its primary akta.pro industry code is HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals, with a secondary code of HLAIAIAD, Rare Neurology & Neurodegenerative Disorder Therapies. Its NAICS code is 325412 and its SIC code is 2834.